Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BIND-014 |
Synonyms | |
Therapy Description |
BIND-014 is a docetaxel-containing nanoparticle targeted to prostate-specific membrane antigen (PSMA) that gradually releases docetaxel, resulting in tumor cell death (PMID: 26847057, PMID: 31424909). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BIND-014 | BIND-014 is a docetaxel-containing nanoparticle targeted to prostate-specific membrane antigen (PSMA) that gradually releases docetaxel, resulting in tumor cell death (PMID: 26847057, PMID: 31424909). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02479178 | Phase II | BIND-014 | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck (iNSITE2) | Terminated | USA | 1 |